Tenax Therapeutics is facing a class action lawsuit alleging it misled investors about the effectiveness of its drug TNX-103 for pulmonary hypertension. The lawsuit claims the company overstated the drug's clinical and commercial prospects, leading to a nearly 90% drop in its stock price after disappointing Phase 3 trial results were announced in August 2026. Investors who bought Tenax securities between November 2023 and August 2026 can seek to become lead plaintiff in the case by December 28, 2026. The lawsuit is filed under the Securities Exchange Act of 1934 and is being handled by Robbins Geller Rudman & Dowd LLP.
Tenax Therapeutics class action lawsuit news provides context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 28, 2026 05:02 WIB: out of 150 priced US health-sector stocks, 90 rose and 60 fell. Notable movers include Recursion Pharmaceuticals Inc (RXRX) at USD 4.04 with a 6.32% increase and 99% sell order activity, Dyne Therapeutics Inc (DYN) at USD 16.61 with a 5.66% rise, and Summit Therapeutics Inc (SMMT) at USD 15.30 with a 5.52% gain.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Pomerantz LLP is investigating Mueller Industries for potential securities fraud following the company's Q3 fiscal 2026 earnings report, which showed earnings per share of $1.00, below analyst estimates of $1.05 to $1.08. The company also reported a ...
Silvercorp Metals announced a 13% decline in preliminary Q2 revenue to $72.1 million, caused by significant production shortfalls at its Ying Mining District due to safety upgrades. Silver, lead, and zinc outputs fell sharply by 41%, 41%, and 51% res...
Lufax Holding Ltd posted a net loss of RMB1.49 billion in Q3 2026, up from RMB380 million a year earlier, driven by increased credit impairment losses and higher income tax expenses. Total income slightly declined by 4.6% to RMB6.18 billion, while ne...
Nokia Oyj is rated Buy due to strong demand in its Optical and IP Networks segments, driven by previous design wins and new contracts with hyperscalers. The company expects 25%-30% growth in these areas by 2027, supported by margin improvements from ...
